Imagine the challenge — a UK-based biotech company gains EMA (formerly known as EMEA) approval for a new compound, with no mainland European sales infrastructure to work through the labyrinth of EU state processes. Remember, EMA approval is just the beginning. The challenge was to fast-track a launch in countries as diverse as Italy, Spain, France, Belgium, Netherlands, Germany, Austria and Sweden — each with its own local requirements.

Read how Quintiles established a pan-European infrastructure, recruited senior management and was achieving KPIs across 12 countries in just eight months.